A review of the current scientific and regulatory status of nanomedicines and the challenges ahead

PDA Journal of Pharmaceutical Science and Technology

Volumn 65, Issue 2, 2011, Pages 177-195

  Hock, Sia Chong ^a   Ying, Yan Mei ^b   Wah, Chan Lai ^b  

^a HEALTH SCIENCES AUTHORITY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Control in manufacturing; Current regulatory status; Nanomedicines; Quality and safety

Indexed keywords

GOLD NANOPARTICLE; LIPOSOME; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; POLYMER; QUANTUM DOT; DRUG;

ADVERSE DRUG REACTION; BLEACHING; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG MANUFACTURE; DRUG NOMENCLATURE; DRUG QUALITY; DRUG SAFETY; DRUG SOLUBILITY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG UPTAKE; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; MICELLE; NANOMEDICINE; NANOSUSPENSION; NANOTOXICOLOGY; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OCCUPATIONAL SAFETY; PARTICLE SIZE; PATIENT SAFETY; PRACTICE GUIDELINE; REVIEW; SHELF LIFE; TREATMENT RESPONSE; CHEMISTRY; DRUG DELIVERY SYSTEM; LEGISLATION AND JURISPRUDENCE; MEDICINAL CHEMISTRY; NANOTECHNOLOGY;

CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS;

EID: 83755207342     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (156)

1. Bawa, R.; Bawa, S. R.; Maebius, S. T.; Flinn, T.; Wei, C. Protecting new ideas and inventions in nanomedicine with patents. Nanomedicine 2005, 1 (2), 150 -158.
2. Nijhara, R.; Balakrishnan, K. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomedicine 2006, 2 (2), 127-136. (Pubitemid 43956611)
3. Helmus, M. N. The need for rules and regulations. Nature Nanotechnology 2007, 2, 333-334. (Pubitemid 46878175)
4. Chan, V. S. W. Nanomedicine: An unresolved regulatory issue. Regulatory Toxicology and Pharmacology 2006, 46 (3), 218 -224.
5. Bogunia-Kubik, K.; Sugisaka, M. From molecular biology to nanotechnology and nanomedicine. Biosystems 2002, 65 (2-3), 123-138. (Pubitemid 34586773)
6. Freitas, J. R. A. What is nanomedicine? Nanomedicine 2005, 1 (1), 2-9.
7. Vega-Villa, K. R.; et al. Clinical toxicities of nanocarrier systems. Advanced Drug Delivery Reviews 2008, 60 (8), 929 -938.
8. Yih, T. C.; Wei, C. Nanomedicine in cancer treatment. Nanomedicine 2005, 1 (2), 191-192. (Pubitemid 43963618)
9. Moore, R. Nanomedicine, why is it different? NANO Magazine 2009, Dec 14 (Issue 8). available from http://www.nano.org.uk/articles/index.php?article=25 (accessed Dec 2009).
10. Mornet, S.; et al. Magnetic nanoparticle design for medical applications. Progress in Solid State Chemistry 2006, 34 (2- 4), 237-247.
11. Nicholls, H. Solving insoluble drug delivery. Drug Discovery Today 2003, 8 (14), 612- 612.
12. Rasenack, N.; Muller, B. W. Micron-size drug particles: common and novel micronization techniques. Pharmaceutical Development and Technology 2004, 9 (1), 1-13. (Pubitemid 38258252)
13. Labhasetwar, V. Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery. Current Opinion in Biotechnology 2005, 16 (6), 674-680. (Pubitemid 41654647)
14. Wei, C.; Yamato, M.; Wei, W.; Zhao, X.; Tsumoto, K.; Yoshimura, T.; Ozawa, T.; Chen, Y. J. Genetic Nanomedicine and Tissue Engineering. Medical Clinics of North America 2007, 91 (5), 889 - 898.
15. Park, J. H.; Lee, S.; Kim, J.-H.; Park, K.; Kim, K.; Kwon, I. C. Polymeric nanomedicine for cancer therapy. Progress in Polymer Science 2008, 33 (1), 113-137. (Pubitemid 350278530)
16. Kabanov, A. V.; Gendelman, H. E. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Progress in Polymer Science 2007, 32 (8 -9), 1054 -1082.
17. Tong, R. T.; Boucher, Y.; Kozin, S. V.; Winkler, F.; Hicklin, D. J.; Jain, R. K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64 (11), 3731- 6.
18. Brewer, M.; Zhang, T.; Dong, W.; Rutherford, M.; Tian, Z. R. Future approaches of nanomedicine in clinical science. Medical Clinics of North America 2007, 91 (5), 963-1016. (Pubitemid 47361209)
19. Rannard, S.; Owen, A. Nanomedicine: not a case of "one size fits all." Nano Today 2009, 4 (5), 382-384.
20. Bawarski, W. E.; Chidlowsky, E.; Bharali, D. J.; Mousa, S. A. Emerging nanopharmaceuticals. Nanomedicine 2008, 4 (4), 273-282.
21. Zuo, L.; Wei, W.; Morris, M.; Wei, J.; Gorbounov, M.; Wei, C. New technology and clinical applications of nanomedicine. Medical Clinics of North America 2007, 91 (5), 845-862. (Pubitemid 47361207)
22. Lockman, P.; Mumper, R. J.; Khan, M. A.; Allen, D. D. Nanoparticle technology for drug delivery across the blood- brain barrier. Drug Dev. Ind. Pharm. 2002, 28, 1-13. (Pubitemid 34279373)
23. Kamiya, S.; Kurita, T.; Miyagishima, A.; Itai, S.; Arakawa, M. Physical properties of griseofulvin-lipid nanoparticles in suspension and their novel interaction mechanism with saccharide during freeze-drying. European Journal of Pharmaceutics and Biopharmaceutics. In press.
24. Muller, R. H.; Keck, C. M. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. Journal of Biotechnology 2004, 113 (1-3), 151-170. (Pubitemid 39237077)
25. Musthaba, S. M.; Baboota, S.; Ahmed, S.; Ahuja, A.; Ali, J. Status of novel drug delivery technology for phytotherapeutics. Expert Opinion on Drug Delivery 2009, 6 (6), 625- 637.
26. Jacobs, C.; Muller, R. H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 2002, 19 (2), 189 -194.
27. Farokhzad, O. C.; Langer, R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Advanced Drug Delivery Reviews 2006, 58 (14), 1456 -1459.
28. Arunkumar, N.; Deecaraman, M.; Rani, C. Nanosuspension technology and its applications in drug delivery. Asian Journal of Pharmaceutics 2009, 3 (3), 168 -173.
29. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Nanomedicine: current status and future prospects. The FASEB Journal 2005, 19, 311-330. (Pubitemid 40316520)
30. The Royal Society and the Royal Academy of Engineering. Nanoscience and nanotechnologies: opportunities and uncertainties. 2004; available from www.nanotec.org.uk/finalReport.htm (accessed Dec 2009).
31. Hagens, W. I.; Oomen, A. G.; de Jong, W. H.; Cassee, F. R; Sips, A. J. What do we (need to) know about the kinetic properties of nanoparticles in the body? Regulatory Toxicology and Pharmacology 2007, 49 (3), 217-229. (Pubitemid 350087396)
32. Brown, D. M.; Wilson, M. R.; MacNee, W.; Stone, V.; Donaldson, K. Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol. Appl. Pharmacol. 2001, 175, 191-199. (Pubitemid 32917742)
33. Park, K.; Lee, D.; Rai, A.; Mukherjee, D.; Zachariah, M. R. Size-resolved kinetic measurements of aluminium nanoparticle oxidation with single particle mass spectrometry. J. Phys. Chem., B 2005, 109 (15), 7290 -7299.
34. Maynard, A. D. Nanotechnology: the next big thing or much ado about nothing? Ann. Occup. Hyg. 2007, 51 (1), 1-12. (Pubitemid 46096390)
35. Busuttil, K. Delivering a lethal dose: nanomedicine. Nano Today 2007, 2 (5), 10 -10.
36. Panyam, J.; Dali, M. M.; Sahoo, S. K.; Ma, W.; Chakravarthi, S. S.; Amidon, G. L.; Levy, R. J.; Labhasetwar, V. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. Journal of Controlled Release 2003, 92 (1-2), 173-187. (Pubitemid 37130131)
37. Roszek, B. Nanotechnology in Medical Devices. Centre for Biological Medicines and Medical Technology, National Institute for Public Health and the Environment (RIVM): Bilthoven, The Netherlands, 2004, available from http://www.mhra.gov.uk/home/idcplg?IdcService=GET-FILE&dDocName= CON2022822&RevisionSelection-Method=Latest (accessed Dec 2009).
38. Lee, I.; Zamora, L. Australia and New Zealand Horizon Scanning Network Bulletin; 2007. available from http://www.health.gov.au/internet/horizon/ publishing.nsf/Content/5190FF1EEFB296C4CA2575AD0080F33A/$File/ Apr%2007%20ANZHSN%20Newsletter%202.pdf (accessed Dec 2009).
39. Wei, C.; Wei, W.; Morris, M.; Kondo, E.; Gorbounov, M.; Tomalia, D. A. Nanomedicine and drug delivery. Medical Clinics of North America 2007, 91 (5), 863- 870.
40. Torchilin, V. P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. The AAPS Journal 2007, 9 (2), E128 -E147.
41. Xiong, X.-B., Uludag, H.; Lavasanifar, A. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials 2009, 30 (2), 242-253.
42. Simone, E. A.; Dziubla, T. D.; Colon-Gonzalez, F.; Discher, D. E.; Muzykantov, V. R. Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules 2007, 8 (12), 3914 -3921.
43. Torchilin, V. P. Multifunctional nanocarriers. Advanced Drug Delivery Reviews 2006, 58 (14), 1532-1555. (Pubitemid 44822608)
44. Singh, R.; Lillard Jr., J. W. Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology 2009, 86 (3), 215-223.
45. Son, S. J.; Bai, X.; Lee, S. B. Inorganic hollow nanoparticles and nanotubes in nanomedicine: Part 1. Drug/gene delivery applications. Drug Discovery Today 2007, 12 (15-16), 650 - 656.
46. Parveen, S.; Sahoo, S. K. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clinical Pharmacokinetics 2006, 45 (10), 965-988. (Pubitemid 44436001)
47. Cattel, L.; Ceruti, M.; Dosio, F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 2003, 89 (3), 237-249. (Pubitemid 37014112)
48. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in maglinant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes (Doxil). Cancer Res. 1994, 54, 987-992. (Pubitemid 24085451)
49. Martin, F. J.; Lasic, D. D.; Papahadjopoulos, D. Clinical Pharmacology and Antitumor Efficacy of DOXIL (Pegylated Liposomal Doxorubicin). In Medical Applications of Liposomes; Elsevier Science B. V.: Amsterdam, 1998; pp 635- 688.
50. Northfelt, D.; Stewart, S. DOXIL (Pegylated Liposomal Doxorubicin) as First-Line Therapy of AIDS-Related Kaposi's Sarcoma (KS): Integrated Efficacy and Safety Results from Two Comparative Trials. 4th Conference on Retroviral Opportunistic Infections, Washington, DC, 1997.
51. Jones, M. C.; Leroux, J. C. Polymeric micelles - a new generation of colloidal drug carriers. European Journal of Pharmaceutics and Biopharmaceutics 1999, 48 (2), 101-111.
52. Kwon, G. S.; Okano, T. Polymeric micelles as new drug carriers. Advanced Drug Delivery Reviews 1996, 21 (2), 107-116. (Pubitemid 26401713)
53. Rapoport, N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Progress in Polymer Science 2007, 32 (8 -9), 962-990.
54. Nakanishi, T.; Fukushima, S.; Okamoto, K.; Suzuki, M.; Matsumura, Y.; Okano, T.; Sakurai, Y.; Kataoka, K. Development of the polymer micelle carrier system for doxorubicin. Journal of Controlled Release 2001, 74 (1-3), 295-302. (Pubitemid 32727635)
55. Choi, K.-C.; Bang, J. Y.; Kim, P. I.; Kim, C.; Song, C. E. Amphotericin B-incorporated polymeric micelles composed of poly(d,l-lactide-coglycolide)/ dextran graft copolymer. International Journal of Pharmaceutics 2008, 355 (1- 2), 224 -230.
56. Shiraishi, K., Kawano, K.; Minowa, T.; Maitani, Y.; Yokoyama, M. Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents. Journal of Controlled Release 2009, 136 (1), 14 -20.
57. Duncan, R. Nano-sized particles as "nanomedicines."Available from http://www.mhra.gov.uk/home/idcplg?IdcService=GET-FILE&dDocName= CON2022821&RevisionSelectionMethod=Latest (accessed Dec 2009).
58. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer 2001, 37 (13), 1590 -1598.
59. Zhang, J. A.; Anyarambhatla, G.; Ma, L.; Ugwu, S.; Xuan, T.; Sardone, T.; Ahmad, I. Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. European Journal of Pharmaceutics and Biopharmaceutics 2005, 59 (1), 177-187. (Pubitemid 39573451)
60. Nanoparticulate Drug Delivery Systems; Thassu, D., Deleers, M., Pathak, Y., Eds.; Informa Helathcare USA, Inc.: New York, 2007.
61. Edwards, S. A, The Nanotech Pioneers: Where Are They Taking Us? Wiley-VCH Verlag GmgH & Co.: Weinheim, Germany, 2006.
62. Harries, M.; Ellis, P.; Harper, P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 2005, 23, 7768 -7771.
63. Bach, I. C. What is Bioimaging? Bioimaging Workshop 2009, Faculty of Life Sciences, University of Copenhagen, 2009; last updated Mar 2009; available from http://www.bioimaging.life.ku.dk/What-is-bioimaging.aspx (accessed Dec 2009).
64. Chen, P. C.; Mwakwari, S. C.; Oyelere, A. K. Gold nanoparticles: from nanomedicine to nanosensing. Nanotechnology 2008, 1, 45- 66.
65. Kim, J.-H.; Park, K.; Nam, H. Y.; Lee, S.; Kim, K.; Kwon, I. C. Polymers for bioimaging. Progress in Polymer Science 2007, 32 (8 -9), 1031-1053.
66. Sharma, P.; Brown, S.; Walter, G.; Santra, S.; Moudgil, B. Nanoparticles for bioimaging. Advances in Colloid and Interface Science 2006, 123-126, 471- 485.
67. Hild, W. A.; Breunig, M.; Goepferich, A. Quantum dots - nano-sized probes for the exploration of cellular and intracellular targeting. European Journal of Pharmaceutics and Biopharmaceutics 2008, 68 (2), 153-168.
68. Derfus, A. M.; Chan, W. C. W.; Bhatia, S. N. Probing the cytotoxicity of semiconductor quantum dots. Nano Letters 2004, 4 (1), 11-18. (Pubitemid 38167855)
69. Yang, F.; Li, Y.; Chen, Z.; Zhang, Y.; Wu, J.; Gu, N. Superparamagnetic iron oxide nanoparticle-embedded encapsulated microbubbles as dual contrast agents of magnetic resonance and ultrasound imaging. Biomaterials 2009, 30 (23-24), 3882-3890.
70. Thorek, D. L. J.; Chen, A. K.; Czupryna, J.; Tsourkas, A. Molecular Imaging of Cancer with Superparamagnetic Iron-Oxide Nanoparticles. In Cancer Imaging; Academic Press: San Diego, CA, 2008; pp 85-95.
71. Li, J. L.; Wang, L.; Liu, X. Y.; Zhang, Z. P.; Guo, H. C.; Liu, W. M.; Tang, S. H. In vitro cancer cell imaging and therapy using transferrin- conjugated gold nanoparticles. Cancer Letters 2009, 274 (2), 319 -326.
72. Kawasaki, E. S.; Player, A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine: Nanotechnology, Biology and Medicine 2005, 1 (2), 101-109. (Pubitemid 43963616)
73. Liong, M.; Lu, J.; Kovochich, M.; Xia, T.; Ruehm, S. G.; Nel, A. E.; Tamanoi, F.; Zink, J. I. Multifunctional inorganic nanopartices for imaging, targeting and drug delivery. ACS Nano 2008, 2 (5), 889 - 896.
74. Kim, J. H.; Morikis, D.; Ozkan, M. Adaptation of inorganic quantum dots for stable molecular beacons. Sensors and Actuators, B 2004, 102, 315-319.
75. Patterson, G. H.; Knobel, S. M.; Sharif, W. D.; Kain, S. R.; Piston, D. W. Use of the green fluorescent protein and its mutants in quantitative fluorescence microscopy. Biophysical Journal 1997, 73, 2782-2790. (Pubitemid 27471487)
76. Cavalcanti, A.; Shirinzadeh, B.; Kretly, L. C. Medical nanorobotics for diabetes control. Nanomedicine 2008, 4 (2), 127-138.
77. Li, G.; Xi, N.; Wang, D. H. In situ sensing and manipulation of molecules in biological samples using a nanorobotic system. Nanomedicine 2005, 1 (1), 31- 40.
78. Ying, L.; Bruckbauer, A.; Rothery, A. M.; Korchev, Y. E.; Klenerman, D. Programmable delivery of DNA through a nanopipet. Anal. Chem. 2002, 74 (6), 1380 -1385.
79. Li, S. Q.; Zhu, R. R.; Zhu, H.; Xue, M.; Sun, X. Y; Yao, S. D.; Wang, S. L. Nanotoxicity of TiO2 nanoparticles to erythrocyte in vitro. Food and Chemical Toxicology 2008, 46 (12), 3626 -3631.
80. Geiser, M.; Rothen-Rutishauser, B.; Kapp, N.; Schurch, S.; Kreyling, W.; Schulz, H.; Semmler, M.; Hof, V. I.; Heyder, J.; Gehr, P. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ. Health Perspect. 2005, 113 (11), 1555-1560. (Pubitemid 41614911)
81. Mahmoudi, M., Simchi, A.; Milani, A. S.; Stroeve, P. Cell toxicity of superparamagnetic iron oxide nanoparticles. Journal of Colloid and Interface Science 2009, 336 (2), 510 -518.
82. Chithrani, B. D.; Stewart, J.; Allen, C.; Jaffray, D. A. Intracellular uptake, transport, and processing of nanostructures in cancer cells. Nanomedicine 2009, 5 (2), 118 -127.
83. Geiser, M.; Casaulta, M.; Kupferschmid, B.; Schulz, H.; Semmler-Behuke, M.; Kreyling, W. The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. Am. J. Respir. Cell Mol. Biol. 2008, 38 (3), 371-376. (Pubitemid 351567707)
84. Lee, K.; Yang, Y. S.; Kwon, S. J.; Lee, J. S.; Choi, S. J.; Seo, H. S.; Kang, M. S.; Lee, B. C.; Kim, S. N.; Yang, H. S.; Han, Y. A.; Ryu, H. J.; Heo, J. D.; Cho, K. H.; Song, C. W.; Cho, K. H. Lung injury study by 15 days inhalation exposure of titanium dioxide nanoparticles in rats. Toxicology Letters 2009, 189 (Supplement 1), S186 -S186.
85. Cho, M.; Cho, W. S.; Choi, M.; Kim, S. J.; Han, B. S.; Kim, S. H.; Kim, H. O.; Sheen, Y. Y.; Jeong, J. The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicology Letters 2009, 189 (3), 177-183.
86. Kobayashi, N.; Naya, M.; Endoh, S.; Maru, J.; Yamamoto, K.; Nakanishi, J. Comparative pulmonary toxicity study of nano-TiO2 particles of different sizes and agglomerations in rats: different short- and long-term post-instillation results. Toxicology 2009, 264 (1-2), 110 -118.
87. Nishimori, H.; Kondoh. M.; Isoda, K.; Tsunoda, S.; Tsutsumi, Y.; Yagi, K. Silica nanoparticles as hepatotoxicants. European Journal of Pharmaceutics and Biopharmaceutics 2009, 72 (3), 496 -501.
88. Wang, J. X.; Fan, Y. B.; Gao, Y.; Hu, Q. H; Wang, T. C. TiO2 nanoparticles translocation and potential toxicological effect in rats after intraarticular injection. Biomaterials 2009, 30 (27), 4590 - 4600.
89. Oberdorster, G.; Sharp, Z.; Atudorei, V.; Elder, A.; Gelein, R.; Kreyling, W.; Cox, C. Translocation of inhaled ultrafine particles to the brain. Inhalation Toxicology 2004, 16 (6 -7), 437- 445.
90. de Jong, W. H.; Roszek, B.; Geertsma, R. E. Nanotechnology in medical applications: possible risks for human health. RIVM report 265001002/2005, Department of Pharmaceutical Affairs and Medical Technology of the Dutch Ministry of Health, Welfare, and Sports, Bilthoven, The Netherlands, 2005.
91. Karlsson, H. L.; Gustafsson, J.; Cronholm, P.; Moller, L. Size-dependent toxicity of metal oxide particles - a comparison between nano- and micrometer size. Toxicology Letters 2009, 188 (2), 112-118.
92. Warheit, D. B.; Webb, T. R.; Sayes, C. M.; Colvin, V. L.; Reed, K. L. Pulmonary instillation studies with nanoscale TiO2 rods and dots in rats: toxicity is not dependent upon particle size and surface area. Toxicological Sciences 2006, 91 (1), 227-236.
93. Warheit, D. B.; Laurence, B. R.; Reed, K. L.; Roach, D. H.; Reynolds, G. A.; Webb, T. R. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Respiratory Toxicology 2004, 77 (1), 117-125. (Pubitemid 38128651)
94. Semmler-Behnke, M.; Takenaka, S.; Fertsch, S.; Wenk, A.; Seitz, J.; Mayer, P.; Oberdorster, G.; Kreyling, W. G. Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airways epithelium. Environ. Health Perspect. 2007, 115 (5), 728 -733.
95. Watari, F.; Takashi, N.; Yokoyama, A.; Uo, M.; Akasaka, T.; Sato, Y.; Abe, S.; Totsuka, Y.; Tohji, K. Material nanosizing effect on living organisms: non-specific, biointeractive, physical size effects. J. R. Soc. Interface 2009, 6 (Suppl. 3), 371-388.
96. Chithrani, B. D.; Ghazani, A. A.; Chan, W. C. W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Letters 2006, 6 (4), 662- 668.
97. Wallace, W. E.; Keane, M. J.; Murray, D. K.; Chisholm, W. P.; Maynard, A. D.; Ong, T. M. Phospholipid lung surfactant and nanoparticle surface toxicity: lessons from diesel soots and silicate dusts. Journal of Nanoparticle Research 2007, 1 (9), 23-38.
98. Oberdörster, E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health Perspect. 2004, 112 (10), 1058 -1062.
99. Brown, S. C.; Kamal, M.; Nasreen, N.; Baumuratov, A.; Sharma, P.; Antony, V. B.; Moudgil, B. M. Influence of shape, adhesion and simulated lung mechanics on amorphous silica nanoparticle toxicity. Advanced Powder Technology 2007, 18 (1), 69 -79.
100. Radomski, A.; Jurasz, P.; Alonso-Escolano, D.; Drews, M.; Morandi, M.; Malinski, T.; Radomski, M. W. Nanoparticle-induced platelet aggregation and vascular thrombosis. British Journal of Pharmacology 2005, 146 (6), 882- 893.
101. Costigan S. The toxicology of nanoparticles used in healthcare products. 2006. Available from http://www.mhra.gov.uk/home/idcplg?IdcService=GET- FILE&dDocName=CON2025205&Revision-SelectionMethod=Latest (accessed Dec 2009).
102. Lockman, P. R.; Koziara, J. M.; Mumper, R. J.; Allen, D. D. Nanoparticle surface charges alter blood- brain barrier integrity and permeability. Journal of Drug Targeting 2004, 12 (9 -10), 635- 641.
103. Cho, S. J.; Maysinger, D.; Jain, M.; Roder, B.; Hackbarth, S.; Winnik, F. M. Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir 2007, 23 (4), 1974 -1980.
104. Choi, A. O.; Cho, S. J.; Desbarats, J.; Lovric, J.; Maysinger, D. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J. Nanobiotechol. 2007, 5 (1).
105. 105, Kesisoglou, F.; Panmai, S.; Wu, Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Advanced Drug Delivery Reviews 2007, 59 (7), 631- 644.
106. Pauluhn, J. Pulmonary toxicity and fate of agglomerated 10 and 40 nm aluminium oxyhydroxides following 4-week inhalation exposure of rats: toxic effects are determined by agglomerated, not primary particle size. Toxicological Sciences 2009, 109 (1), 152-167.
107. Peukert, W.; Schwarzer, H.-C.; Stenger, F. Control of aggregation in production and handling of nanoparticles. Chemical Engineering and Processing 2005, 44 (2), 245-252. (Pubitemid 39365072)
108. Teeguarden, J. G.; Hinderliter, P. M.; Orr, G.; Thrall, B. D.; Pounds, J. G. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicological Sciences 2006, 95 (2), 300 -312.
109. Mohanraj, V.; Chen, Y. Nanoparticles - a review. Tropical Journal of Pharmaceutical Research 2006, 5 (1), 561-573.
110. Powers, K. W.; Brown, S. C.; Krishna, V. B.; Wasdo, S. C.; Moudgil, B. M.; Roberts, S. M. Research strategies for safety evaluation of nanomaterials. Part VI. Characterization of nanoscale particles for toxicological evaluation. Toxicological Sciences 2006, 90 (2), 296 -303.
111. Borm, P. J.; Robbins. D.; Haubold, S.; Kuhlbusch, T.; Fissan, H.; Donaldson, K.; Schins, R.; Stone, V.; Kreyling, W.; Lademann, J.; Krutmann, J.; Warheit, D.; Oberdorster, E. The potential risks of nanomaterials: a review carried out for ECETOC. Particle and Fibre Toxicology 2006, 3 (11).
112. Rancan, F.; Rosan, S.; Boehm, F.; Cantrell, A.; Brellreich, M.; Schoenberger, Hirsch, A.; Moussa, F. Cytotoxicity and photocytotoxicity of a dendritic C(60) mono-adduct and a malonic acid C(60) tris-adduct on Jurkat cells. J. Photochem. Photobiol. 2002, 67 (3), 157-162.
113. FDA. Frequently asked questions (nanotechnology). Science & Research, U.S. Department of Health & Human Services, U.S. FDA; last updated May 2009; available from http://www.fda.gov/ScienceResearch/SpecialTopics/ Nanotechnology/FrequentlyAskedQuestions/default.htm (accessed Dec 2009).
114. MHRA. How we regulate nanotechnology. Nanotechnology, MHRA; last updated Feb 2008; available from http://www.mhra.gov.uk/Howweregulate/Nanotechnology/ index.htm (accessed Dec 2009).
115. TGA. Nanotechnology and therapeutic products. Department of Health and Ageing, Therapeutic Goods Administration, Australian Government; last updated Jul 2008; available from http://www.tga.gov.au/meds/qanano.htm (accessed Dec 2009).
116. D'Silva, J.; Calster, G. V. Regulating nanomedicine: a European perspective. Nature Precedings 2008.
117. TGA. Medicines regulation and the TGA. Department of Health and Ageing, Therapeutic Goods Administration, Australian Government; Last updated Aug 2009; available from http://www.tga.gov.au/docs/html/medregs.htm (accessed Dec 2009).
118. MHRA. Making regulatory decisions about medicines and medical devices. 2007; available from http://www.mhra.gov.uk/home/idcplg?IdcService=GET- FILE&dDocName=CON2030689&Revision SelectionMethod=Latest&noSaveAs= 0&Rendition=WEB (accessed Dec 2009).
119. Health Canada. Access to therapeutic products: the regulatory process in Canada. About Health Canada, Health Canada; last updated Jun 2006; available from http://www.hc-sc.gc.ca/ahc-asc/pubs/hpfb-dgpsa/access-therapeutic-acces- therapeutique-eng.php (accessed Dec 2009).
120. Finan, C. Federal nanotech risk research plan still comes up short. 2008; available from http://www.nanotechproject.org/process/files/6051/nano- nniordreleasefinal.pdf (accessed Dec 2009).
121. MHRA. Nanotechnology. In General Safety Information and Advice, Safety Information, MHRA; last updated Mar 2008; available from http://www.mhra.gov.uk/ Safetyinformation/Generalsafetyinformationandadvice/Technicalinformation/ Nanotechnology/index.htm (accessed Dec 2009).
122. U.S. FDA and Nanotechnology Task Force. Nanotechnology task force report. 2007; available from http://www.fda.gov/ScienceResearch/SpecialTopics/ Nanotechnology/NanotechnologyTaskForceReport2007/default.htm#organization (accessed Dec 2009).
123. NCI. Nanotechnology characterization lab. National Cancer Institute; last updated 2009; available from http://ncl.cancer.gov/ (accessed Dec 2009).
124. Bucher, J. R. Evaluating human health risks from nanomaterials. In National Toxicology Program; 2006; available from http://www.toxexpo.com/ms/ Bucher.pdf (accessed Dec 2009).
125. TGA. A review of the scientific literature on the safety of nanoparticulate titanium dioxide or zinc oxide in sunscreens. 2009; available from http://www.tga.gov.au/npmeds/sunscreen-zotd.pdf (accessed Dec 2009).
126. MHRA. Conference publications. In Conferences; MHRA; last updated Aug 2008; available from http://www.mhra.gov.uk/ConferencesLearningCentre/ Conferences/Publications/index.htm (accessed Dec 2009).
127. EMA. Medicines and emerging science - post conference presentations from the ad-hoc expert group to nanomedicines. European Medicines Agency; last updated Jan 2010; available from http://www.ema.europa.eu/htms/human/mes/ nanotechnology-workshop.htm (accessed Jan 2010).
128. EMA. Human Medicines - medicines and emerging science - emerging technologies. European Medicines Agency; last updated Jan 2010; available from http://www.ema.europa.eu/htms/human/mes/emergingtechnologies.htm (accessed Dec 2010).
129. HumGen. Research projects. HumGen International; available from http://www.humgen.umontreal.ca/int/projets.cfm?id-projet=97 (accessed Dec 2009).
130. Faunce, T. A., Nanotherapeutics: new challenges for safety and cost-effectiveness regulation in Australia. eMJA 2007, 186 (4), 189-191.
131. Aitken, R.; Creely, K.; Tan, C. Nanoparticles: an occupational hygiene review. 2004; available from http://www.hse.gov.uk/research/rrpdf/rr274.pdf (accessed Dec 2009).
132. John, C.; Monica, J. R. Talking the Talk: Standardizing the Language of Nanotechnology. 2008; available from http://publicaa.ansi.org/sites/apdl/ Documents/News%20and%20Publications/Other%20Documents/ Series%20on%20Nanotechnology%20Standardization/Nano-Law-Report-WG1-08-08.pdf (accessed Dec 2009).
133. National Nanotechnology Initiative. What is nanotechnology? Nanotech Facts, National Nanotechnology Initiative; available from http://www.nano.gov/ html/facts/whatIsNano.html (accessed Dec 2009).
134. Chaudhry, Q.; Blackburn, J.; Floyd, P.; George, C.; Nwaogu, T.; Boxall, A.; Aitken, R. A scoping study to identify gaps in environmental regulation for the products and applications of nanotechnologies. U.K. Department of Environment, Food and Rural Affairs: London, 2006.
135. Nordan, M. M.; Holman, M. W. A prudent approach to nanotechnology environmental, health, and safety risks. Ind. Biotechnol. 2005, 1 (3), 146 -149.
136. Frater, L.; Stokes, E.; Lee. R.; Oriola, T. An overview of the framework of current regulation affecting the development and marketing of nanomaterials. Cardiff University; 2006, available from http://www.dius.gov.uk/~/media/ publications/F/file36167 (accessed Dec 2009).
137. Nagarajan, R. Nanoparticles: Building blocks for nanotechnology. ACS Symposium Series 2008, 996, 2-14.
138. ANSI. About the nanotechnology standards panel. Standards Activities, American National Standards Institute; available from http://www.ansi.org/ standards-activities/standards-boards-panels/nsp/overview.aspx?menuid=3 (accessed Dec 2009).
139. ISO. ISO - technical committees - TC 229 - nanotechnologies. International Organization for Standardization; last updated 2010; available from http://www.iso.org/iso/standards-development/technical-committees/list-of- iso-technical-committees/iso-technical-committee.htm-?commid=381983 (accessed Jan 2010).
140. Luther, W. Industrial application of nanomaterials - chances and risks. 2004. available from http://www.nanowerk.com/nanotechnology/reports/reportpdf/ report27.pdf (accessed Dec 2009).
141. Nanosafe. Nanosafe; Last updated Oct 2009; available from http://www.nanosafe.org/scripts/home/publigen/content/templates/show.asp?P= 55&L=EN&ITEMID=2 (accessed Dec 2009).
142. Webster, T. J. Regulation of nanotechnology: are we doing enough? Int. J. Nanomedicine 2007, 2 (3), 275-276. (Pubitemid 350047772)
143. FDA. Frequently asked questions about combination products. Combination Products, U.S. Department of Health & Human Services, U.S. FDA; Last updated Jul 2009; available from http://www.fda.gov/CombinationProducts/ AboutCombinationProducts/ucm101496.htm (accessed Dec 2009).
144. FDA. Definition of Primary Mode of Action of a Combination Product. 2004, Federal Register.
145. Miller, J. Beyond biotechnology: FDA regulation of nanomedicine. In The Columbia Science and Technology Law Review 2003.
146. Faunce, T. A.; Johnston, K.; Bambrick, H. The Trans-Tasman Therapeutic Products Authority: potential AUSFTA impacts on safety and cost-effectiveness regulation for medicines and medical devices in New Zealand. Victoria University of Wellington Law Review 2006, 37, 365-390.
147. Rejeski, D. FDA-regulated products containing nanotechnology materials. Project on Emerging Nanotechnologies, Woodrow Wilson International Center for Scholars, 2006.
148. TGA. Guidelines for levels and kinds of evidence to support indications and claims. Department of Health and Ageing, Therapeutic Goods Administration, Australia Government; last updated Oct 2007; available from http://www.tga-.gov. au/docs/html/tgaccevi.htm (accessed Dec 2009).
149. TGA. Australian code of good manufacturing practice for medicinal products. 2002; available from http://www.tga.gov.au/DOCS/pdf/gmp-codau.pdf (accessed Dec 2009).
150. Amoabediny, G.; et al. Guidelines for safe handling, use and disposal of nanoparticles. In Nanosafe 2008: International Conference on Safe production and use of nanomaterials; IOP Publishing, 2009.
151. Buzea, C.; Blandino, I. I. P.; Robbie, K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2007, 2 (4), MR17-MR71.
152. Inoue, K., Takano, H.; Yanagisawa, R.; Sakurai, M.; Abe, S.; Yoshino, S.; Yamaki, K.; Yoshikawa, T. Effects of nanoparticles on lung physiology in the presence or absence of antigen. Int. J. Immunopathol. Pharmacol. 2007, 20 (4), 737-744.
153. Furgeson, D. Y. Nanotools for toxicity: assessment of nanomedicines. 2008; available from http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4370s1- 05-Guest-Furgeson.pdf (accessed Dec 2009).
154. EC. Medicinal products for human and veterinary use. In EU Guidelines to Good Manufacturing Practice, 2005.
155. Ng, D.; Huang, P. Y.; Jeng, Y. R.; Liang, H. Nanoparticle removal mechanisms during post-cmp cleaning. Electrochem. Solid-State Lett. 2007, 10 (8), H227-H231. (Pubitemid 46920047)
156. Libman, S., et al. Managing semiconductor manufacturing risk through improved control of nanoparticles in ultrapure water. Available from http://www.fmtdevelop.com/uploads/3/5/4/5/3545567/npcd-itrsroundrobin-2009.pdf (accessed Dec 2009).